Advanced Ovarian Cancer: Triplet Chemotherapy-Immunotherapy Combinations

AGO-OVER 17 BOOST Phase III Trial Results

• November 18, 2022

On November 4, 2022, researchers led by Jacobus Pfisterer from Arbeitsgemeinschaft Gynaekologische Onkologie published AGO-OVER 17 BOOST/GINECO OV118/ENGOT Ov-15 Phase III results in the Journal of Clinical Oncology, evaluating extended bevacizumab duration in first-line ovarian cancer treatment.

Trial Design

Patient Population: Stage IIB-IV advanced epithelial ovarian cancer (n=927)

Treatment Arms:

• Paclitaxel 175 mg/m² + Carboplatin + Bevacizumab 15 mg/kg for 15 months (n=469)
• Paclitaxel 175 mg/m² + Carboplatin + Bevacizumab 15 mg/kg for 30 months (n=458)

Primary Endpoint: Progression-free survival

Key Results

Progression-Free Survival Median:

• 15-month bevacizumab: 24.2 months
• 30-month bevacizumab: 26.0 months
• No significant difference

Overall Survival: No significant difference between groups

Safety Profile

Grade 3-4 adverse events: 29% (15-month group) vs 34% (30-month group), consistent with established safety profile.

Clinical Conclusions

Extended bevacizumab beyond 15 months does not provide additional progression-free or overall survival benefit in first-line advanced ovarian cancer treatment.

Data Source

https://ascopubs.org/doi/abs/10.1200/JCO.22.01010

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Ovarian cancer